Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings Release
Question
Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings Release
Direct answer
Abbott Laboratories gained 2.23% to settle at $101.82 on October 12, 2026, exhibiting relative strength as broader market benchmarks moved lower. The advance comes ahead of the company's scheduled third-quarter earnings release on October 21, 2026. Consensus projections anticipate 9.23% year-over-year EPS growth to $1.42 alongside a 13.52% revenue expansion to $12.91 billion, supported by consistent medical device segment volumes. — bullish pressure on ABT.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-13
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings Release”, revision 1, evidence through 2026-10-13. https://marketontology.com/catalysts/2026-10-13/abbott-rises-2-23-to-101-82-ahead-of-october-21-q3-earnings-release-45cdab
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ABT | ▲Bull | 1–4 weeks | Catalyst Driven | 73 |
Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings Release
Abbott Laboratories gained 2.23% to settle at $101.82 on October 12, 2026, exhibiting relative strength as broader market benchmarks moved lower. The advance comes ahead of the company's scheduled third-quarter earnings release on October 21, 2026. Consensus projections anticipate 9.23% year-over-year EPS growth to $1.42 alongside a 13.52% revenue expansion to $12.91 billion, supported by consistent medical device segment volumes. — bullish pressure on ABT.
Abbott Laboratories gained 2.23% to settle at $101.82 on October 12, 2026, exhibiting relative strength as broader market benchmarks moved lower. The advance comes ahead of the company's scheduled third-quarter earnings release on October 21, 2026. Consensus projections anticipate 9.23% year-over-year EPS growth to $1.42 alongside a 13.52% revenue expansion to $12.91 billion, supported by consistent medical device segment volumes.
- SummaryAbbott Laboratories gained 2.23% to settle at $101.82 on October 12, 2026, exhibiting relative strength as broader market benchmarks moved lower. The advance comes ahead of the company's scheduled third-quarter earnings release on October 21, 2026. Consensus projections anticipate 9.23% year-over-year EPS growth to $1.42 alongside a 13.52% revenue expansion to $12.91 billion, supported by consistent medical device segment volumes.
- ABTDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- ABT closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ABT price vs. pre-event level
- ABT volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-13Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecastABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42ABT
- 2026-10-13Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line GrowthABT IHI XLV+2.53%
- 2026-10-13Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue ForecastABT
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.